Indalpine

Identification

Name
Indalpine
Accession Number
DB08953
Type
Small Molecule
Groups
Investigational, Withdrawn
Description

Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

Structure
Thumb
Synonyms
Not Available
External IDs
LM-5008
International/Other Brands
Upstène (Pharmuka)
Categories
UNII
V35562QSVT
CAS number
63758-79-2
Weight
Average: 228.3327
Monoisotopic: 228.16264865
Chemical Formula
C15H20N2
InChI Key
SADQVAVFGNTEOD-UHFFFAOYSA-N
InChI
InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2
IUPAC Name
3-[2-(piperidin-4-yl)ethyl]-1H-indole
SMILES
C(CC1=CNC2=CC=CC=C12)C1CCNCC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Indalpine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Indalpine.Experimental
AcarboseIndalpine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Indalpine.Approved
AcenocoumarolIndalpine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Indalpine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Indalpine.Approved
Acetylsalicylic acidIndalpine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Indalpine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Indalpine.Approved, Investigational
AlaproclateIndalpine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideIndalpine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Indalpine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Indalpine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Indalpine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Indalpine.Investigational
AlogliptinIndalpine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Indalpine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Indalpine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Indalpine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Indalpine.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indalpine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indalpine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Indalpine.Approved, Illicit
AmoxapineIndalpine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Indalpine.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Indalpine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Indalpine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Indalpine.Approved
AtenololThe serum concentration of Atenolol can be increased when it is combined with Indalpine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Indalpine.Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Indalpine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Indalpine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Indalpine.Experimental
BendroflumethiazideIndalpine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Indalpine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Indalpine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Indalpine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Indalpine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Indalpine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.Approved
BezitramideBezitramide may increase the serotonergic activities of Indalpine.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Indalpine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine.Investigational
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Indalpine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Indalpine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indalpine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Indalpine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Indalpine.Experimental
BromocriptineIndalpine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Indalpine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Indalpine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Indalpine.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Indalpine.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Indalpine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indalpine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Indalpine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Indalpine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Indalpine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Indalpine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Indalpine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Indalpine.Approved, Illicit, Vet Approved
CanagliflozinIndalpine may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Indalpine.Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Indalpine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Indalpine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Indalpine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Indalpine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Indalpine.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Indalpine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Indalpine.Approved, Investigational
CelecoxibIndalpine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Indalpine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Indalpine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Indalpine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Indalpine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Indalpine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Indalpine.Approved
ChlorothiazideIndalpine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indalpine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Indalpine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indalpine.Approved, Vet Approved
ChlorpropamideIndalpine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine.Approved, Withdrawn
ChlorthalidoneIndalpine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Indalpine.Approved
CimetidineThe metabolism of Indalpine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Indalpine.Approved, Vet Approved
CitalopramIndalpine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Indalpine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Indalpine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Indalpine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Indalpine.Investigational
ClomipramineIndalpine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Indalpine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indalpine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Indalpine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Indalpine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indalpine.Approved, Illicit
ClorindioneIndalpine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Indalpine.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Indalpine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Indalpine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Indalpine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Indalpine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indalpine.Approved
CyclopenthiazideIndalpine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyproheptadineThe therapeutic efficacy of Indalpine can be decreased when used in combination with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Indalpine.Approved
DapagliflozinIndalpine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Indalpine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Indalpine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Indalpine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Indalpine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Indalpine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Indalpine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indalpine.Approved, Vet Approved
DextromethorphanIndalpine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Indalpine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Indalpine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Indalpine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Indalpine.Approved, Illicit, Vet Approved
DicoumarolIndalpine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Indalpine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Indalpine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Indalpine.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Indalpine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Indalpine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Indalpine.Approved
DiphenadioneIndalpine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indalpine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Indalpine.Approved, Illicit
DisopyramideIndalpine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Indalpine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Indalpine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Indalpine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Indalpine.Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Indalpine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Indalpine.Investigational
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Indalpine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Indalpine.Experimental, Illicit
DulaglutideIndalpine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Indalpine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Indalpine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indalpine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Indalpine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Indalpine.Investigational
EmpagliflozinIndalpine may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Indalpine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Indalpine.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Indalpine.Experimental
EscitalopramIndalpine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Indalpine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Indalpine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Indalpine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Indalpine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Indalpine.Approved
Ethyl biscoumacetateIndalpine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Indalpine.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Indalpine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Indalpine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Indalpine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Indalpine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Indalpine.Approved
EtodolacIndalpine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Indalpine.Approved
EtoricoxibIndalpine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Indalpine.Illicit, Vet Approved
ExenatideIndalpine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Indalpine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Indalpine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Indalpine.Approved, Illicit, Withdrawn
FenfluramineIndalpine may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylFentanyl may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Indalpine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Indalpine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Indalpine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine.Approved, Illicit
FluindioneIndalpine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Indalpine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Indalpine.Approved, Illicit
FluoxetineIndalpine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indalpine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indalpine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Indalpine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indalpine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Indalpine.Approved
FluvoxamineIndalpine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Indalpine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Indalpine.Approved, Illicit
FurazolidoneFurazolidone may increase the serotonergic activities of Indalpine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indalpine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Indalpine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Indalpine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Indalpine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Indalpine.Investigational
GliclazideIndalpine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIndalpine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIndalpine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Indalpine.Approved, Illicit
GlyburideIndalpine may increase the hypoglycemic activities of Glyburide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Indalpine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Indalpine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indalpine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Indalpine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Indalpine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Indalpine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Indalpine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Indalpine.Experimental
HydrochlorothiazideIndalpine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Indalpine.Approved, Illicit
HydroflumethiazideIndalpine may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneHydromorphone may increase the serotonergic activities of Indalpine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Indalpine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Indalpine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indalpine.Approved
IndapamideIndalpine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Indalpine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Indalpine.Investigational
Insulin AspartIndalpine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIndalpine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIndalpine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIndalpine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIndalpine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIndalpine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Indalpine.Approved
Ioflupane I-123Indalpine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the serotonergic activities of Indalpine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Indalpine.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Indalpine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Indalpine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Indalpine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Indalpine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Indalpine.Approved
L-TryptophanL-Tryptophan may increase the serotonergic activities of Indalpine.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Indalpine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indalpine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Indalpine.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Indalpine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Indalpine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Indalpine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Indalpine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Indalpine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Indalpine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Indalpine.Approved
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Indalpine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Indalpine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Indalpine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Indalpine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Indalpine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Indalpine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Indalpine.Approved
LiraglutideIndalpine may increase the hypoglycemic activities of Liraglutide.Approved
LithiumLithium may increase the serotonergic activities of Indalpine.Approved
LofentanilLofentanil may increase the serotonergic activities of Indalpine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Indalpine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Indalpine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Indalpine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Indalpine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Indalpine.Approved
LumiracoxibIndalpine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Indalpine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Indalpine.Approved
MebanazineMebanazine may increase the serotonergic activities of Indalpine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Indalpine.Experimental
MecaserminIndalpine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Indalpine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Indalpine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Indalpine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Indalpine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Indalpine.Approved
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Indalpine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indalpine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Indalpine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indalpine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine.Approved
MetforminIndalpine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Indalpine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Indalpine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Indalpine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Indalpine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indalpine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Indalpine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Indalpine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Indalpine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine.Approved
MethyclothiazideIndalpine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Indalpine.Experimental
Methylene blueIndalpine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Indalpine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Indalpine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Indalpine.Approved, Investigational
MetolazoneIndalpine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Indalpine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Indalpine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Indalpine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.Approved, Illicit
MifepristoneIndalpine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIndalpine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Indalpine.Approved
MinaprineMinaprine may increase the serotonergic activities of Indalpine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indalpine.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Indalpine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Indalpine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Indalpine.Approved, Withdrawn
MorphineMorphine may increase the serotonergic activities of Indalpine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Indalpine.Approved, Investigational
NabumetoneIndalpine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Indalpine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Indalpine.Approved
NateglinideIndalpine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Indalpine.Approved, Withdrawn
NialamideNialamide may increase the serotonergic activities of Indalpine.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Indalpine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Indalpine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Indalpine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Indalpine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Indalpine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indalpine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Indalpine.Withdrawn
OlanzapineIndalpine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indalpine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Indalpine.Approved
OpiumOpium may increase the serotonergic activities of Indalpine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Indalpine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Indalpine.Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Indalpine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Indalpine.Approved
OxycodoneOxycodone may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indalpine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Indalpine.Approved
ParecoxibIndalpine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Indalpine.Approved
ParoxetineIndalpine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Indalpine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Indalpine.Experimental
PentamidineIndalpine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Indalpine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Indalpine.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Indalpine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Indalpine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Indalpine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Indalpine.Approved
PethidinePethidine may increase the serotonergic activities of Indalpine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Indalpine.Experimental
PhenelzinePhenelzine may increase the serotonergic activities of Indalpine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Indalpine.Experimental
PhenindioneIndalpine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Indalpine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Indalpine.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Indalpine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Indalpine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Indalpine.Withdrawn
PhenprocoumonIndalpine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Indalpine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Indalpine is combined with Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Indalpine.Approved
PioglitazoneIndalpine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indalpine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Indalpine.Approved
PiritramidePiritramide may increase the serotonergic activities of Indalpine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Indalpine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Indalpine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Indalpine.Approved
PolythiazideIndalpine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indalpine.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Indalpine.Approved
PramlintideIndalpine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Indalpine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Indalpine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Indalpine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Indalpine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Indalpine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indalpine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Indalpine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Indalpine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Indalpine.Approved, Vet Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Indalpine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Indalpine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Indalpine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Indalpine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Indalpine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Indalpine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Indalpine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.Approved
QuinethazoneIndalpine may increase the hyponatremic activities of Quinethazone.Approved
QuinineIndalpine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Indalpine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Indalpine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Indalpine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Indalpine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Indalpine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine.Approved, Withdrawn
RepaglinideIndalpine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indalpine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Indalpine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Indalpine.Investigational
RofecoxibIndalpine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Indalpine.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine.Approved
RosiglitazoneIndalpine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineSafrazine may increase the serotonergic activities of Indalpine.Withdrawn
SaxagliptinIndalpine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indalpine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Indalpine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Indalpine.Approved, Withdrawn
SertralineIndalpine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indalpine.Approved, Vet Approved
SitagliptinIndalpine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Indalpine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Indalpine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Indalpine.Approved
SufentanilSufentanil may increase the serotonergic activities of Indalpine.Approved, Investigational
SulfadiazineIndalpine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleIndalpine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleIndalpine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.Approved
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Indalpine.Experimental
SunitinibIndalpine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Indalpine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Indalpine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Indalpine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Indalpine.Investigational
TapentadolTapentadol may increase the serotonergic activities of Indalpine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Indalpine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Indalpine.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Indalpine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Indalpine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Indalpine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indalpine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Indalpine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Indalpine.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indalpine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Indalpine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Indalpine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Indalpine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Indalpine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indalpine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Indalpine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Indalpine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Indalpine.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Indalpine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Indalpine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Indalpine.Approved
TioclomarolIndalpine may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indalpine.Approved
TolazamideIndalpine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideIndalpine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indalpine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Indalpine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Indalpine.Approved
TramadolIndalpine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indalpine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indalpine.Approved
TrazodoneIndalpine may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Indalpine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Indalpine.Vet Approved
TrichlormethiazideIndalpine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Indalpine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indalpine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Indalpine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indalpine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Indalpine.Approved
ValdecoxibIndalpine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Indalpine.Approved, Investigational
VenlafaxineVenlafaxine may increase the serotonergic activities of Indalpine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Indalpine.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Indalpine.Approved
VilazodoneIndalpine may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Indalpine.Experimental
VortioxetineIndalpine may increase the serotonergic activities of Vortioxetine.Approved
WarfarinIndalpine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Indalpine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Indalpine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Indalpine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Indalpine.Approved
ZimelidineIndalpine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Indalpine.Vet Approved
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Indalpine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Indalpine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Indalpine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Indalpine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indalpine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 4,064,255.

General References
  1. Marcin LR, Mattson RJ, Gao Q, Wu D, Molski TF, Mattson GK, Lodge NJ: Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1027-30. doi: 10.1016/j.bmcl.2009.12.043. Epub 2009 Dec 16. [PubMed:20034793]
  2. Galbaud du Fort G: [Hematologic toxicity of antidepressive agents]. Encephale. 1988 Jul-Aug;14(4):307-18. [PubMed:3058454]
External Links
PubChem Compound
44668
PubChem Substance
310264918
ChemSpider
40643
BindingDB
50029150
ChEBI
134939
ChEMBL
CHEMBL276520
Wikipedia
Indalpine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)167 U.S. Patent 4,064,255.
Predicted Properties
PropertyValueSource
Water Solubility0.0125 mg/mLALOGPS
logP3.58ALOGPS
logP3.07ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)17.32ChemAxon
pKa (Strongest Basic)10.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area27.82 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.77 m3·mol-1ChemAxon
Polarizability27.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
3-alkylindoles
Alternative Parents
Aralkylamines / Substituted pyrroles / Piperidines / Benzenoids / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
3-alkylindole / Aralkylamine / Piperidine / Substituted pyrrole / Benzenoid / Pyrrole / Heteroaromatic compound / Secondary aliphatic amine / Secondary amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on May 28, 2014 11:04 / Updated on October 02, 2017 06:11